Situated in the heart of Arroyo Grande, California, Ken Starr MD Wellness Group stands as a beacon of hope and health for the community. The health center's vision springs from the personal journey of its founder, Dr. Ken Starr, who built it originally as a leading-edge addiction treatment center. The clinic has since grown, now providing ketamine therapy, which Dr. Starr refers to as a natural progression of their existing services. Low-dose ketamine treatments have proven remarkably effective for managing chronic pain or mental health conditions, including addiction. This treatment has not only gained worldwide recognition by the World Health Organization for its impressive safety profile, but it has also provided a life-altering remedy for many. Born from a personal tragedy of losing his brother to a heroin overdose, Dr. Starr realized the dire need for focused, cutting-edge treatment centers and started his journey from a modest, closet-sized clinic decades ago.

Recognized by internationally renowned research institutions like Yale, Harvard, and Johns Hopkins University, the Ketamine treatments offered by the Ken Starr MD Wellness Group bring renewed hope and health to the vast majority of its patients. Individuals who haven't found success with conventional medications for their chronic symptoms may find a new lease on life through ketamine therapy. During the 40-minute treatment, patients often experience a sensation of floating or separation from their bodies, which is typical for ketamine treatment. Dr. Starr and his expert team vigilantly oversee each patient's progress, ensuring their comfort throughout the process. The therapy's effects typically become noticeable within 24 hours, but some individuals report significant improvements within just a few hours. The Ken Starr MD Wellness Group offers these Ketamine treatments for individuals who have not benefited much from traditional antidepressants and pain therapies – it should be noted that ketamine therapy has been particularly successful in rapidly reducing suicidal ideation and enabling significant decreases in opiate use among pain or addiction patients.